Mondego Bio

Signadori Bio

This biopharmaceutical company develops a monocyte-based cell therapy platform to treat patients with solid tumours.

PanCancerT

This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.

iOnctura

The company develops precision small-molecule medicines to treat patients with neglected and hard-to-treat solid tumours and cancers.

Neobe

The company develops engineered microbial biotherapeutics designed to disrupt the microenvironment of solid tumours for cancer patients receiving immunotherapy.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.

TwoStep Therapeutics

The company develops peptide-drug conjugates and targeted therapies for patients with solid tumours.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.